Our community of experts has identified a set of common digital clinical measures that are essential for developing Cytokine Release Syndrome (CRS) de-risking products.
We’ve also developed an ontology to help you standardize data collection for assessing CRS onset and severity, whether you’re collecting data manually or digitally, in inpatient or outpatient settings.
These resources are designed to help you streamline data collection efforts, supporting the development of more efficient CRS de-risking products and risk prediction models.
Learn more popup
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Use these measures—fever generation, tachycardia, hypotension, and hypoxia—to detect CRS early, capture critical data, and take action before complications arise, prioritizing patient safety and reducing risks.
By using this roadmap, you’ll explore important milestones that inform the development of your CRS de-risking product—thereby enhancing patient outcomes, optimizing care, and accelerating drug development.